

**Bioconjugation Market by Product (Consumables, Instruments (Chromatography, Spectrometry)), Service (Conjugation, Analytical), Technique (Chemical, Click Chemistry), Biomolecule (Antibodies), Application (Therapeutics (ADC), R&D) - Global Forecast to 2029**

Market Report | 2025-02-01 | 683 pages | MarketsandMarkets

**AVAILABLE LICENSES:**

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

**Report description:**

The bioconjugation market is expected to grow to USD 10.86 billion by 2029, up from USD 5.27 billion in 2024, at a CAGR of 15.6% between 2024 and 2029. Several key factors impact the growth of the bioconjugation market. The development of targeted therapeutics such as ADCs is expected to be greatly supported by bioconjugation, as the need for more accurate and potent cancer treatments grows. Furthermore, there is a growing focus on technological developments and outsourcing services. Furthermore, emerging countries provide significant development opportunities, and the expanding applications of bioconjugation are expected to drive the market further.

"The antibody conjugation segment accounted for the largest share of by conjugation type segment for the bioconjugation services market in 2023."

In 2023, the antibody conjugation segment accounted for the largest share of the global bioconjugation services market by conjugation type. The antibody conjugation segment dominates the bioconjugation services market because it is widely used in developing targeted treatments, particularly for cancer. Antibody-drug conjugates (ADCs) enable accurate drug delivery by targeting specific antigens on tumor cells, minimizing off-target effects and toxicity. The favourable results of ADCs in clinical trials, as well as their approval to treat a variety of malignancies, including HER2-positive breast cancer, have increased demand for antibody-based conjugation services.

"The antibodies segment accounted for the largest share of by biomolecule type segment for the bioconjugation products market in 2023."

In 2023, the antibodies segment accounted for the largest share of the global bioconjugation products market by biomolecule

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

type. The most prominent biomolecule type in the bioconjugation products market is antibodies, especially monoclonal antibodies, which are dominantly used in the development of Antibody-Drug Conjugates (ADCs) with higher accuracy in targeting. Antibodies are integrally used in oncology and have led to several FDA-approved ADC therapies such as Adcetris and Kadcyla. These therapeutic antibodies conjugated with cytotoxic drugs through bioconjugation techniques allow for targeted treatment while minimizing systemic toxicity. Increasing clinical trials and FDA approvals for the drugs based on antibodies further drive the growth of this segment.

"In 2023, the US remained to dominate the bioconjugation market."

The US dominated the North American bioconjugation market in 2023. The US is the world's largest biopharmaceutical market and the leader in biopharmaceutical research and investment. The United States also has a strong healthcare infrastructure, which encourages research and development in the life sciences. Additionally, the significant presence of many biopharmaceutical companies and growing research activities in the biotechnology industry are propelling market growth in the US. Moreover, the growing prevalence of cancer is also driving the growth of the bioconjugation market.

In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the bioconjugation marketplace.

-□By Respondent: Supply Side- 70% and Demand Side 30%

-□By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%

-□By Region: North America - 40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%

Danaher Corporation (US); Lonza (Switzerland); Thermo Fisher Scientific Inc. (US); Merck KGaA (Germany); AbbVie Inc. (US); WuXi Biologics (Cayman) Inc. (China); Sartorius AG (Germany); are some of the key players in the bioconjugation market.

The study includes an in-depth competitive analysis of these key players in the bioconjugation market, with their company profiles, recent developments, and key market strategies

#### Research Coverage:

This research report categorizes the bioconjugation market by product type (consumables {□reagents and kits [linker and crosslinking reagents & kits, labeling reagents & kits, □modification reagents & kits, other reagents & kits], labels [fluorescent tags, enzymes, haptens, polymers, bead coupling, □other labels], other consumables}, instruments {chromatography systems, mass spectrometers, spectroscopy instruments, flow cytometers, electrophoresis equipment, filtration systems, mixers/shakers, incubators, □other instruments}), technique (chemical conjugation, click chemistry, enzyme-mediated conjugation, photoreactive crosslinking, □other techniques), biomolecule type (antibodies, peptides, proteins, oligonucleotides, □other biomolecules), application (therapeutics {antibody-drug conjugates (ADCs), peptide-drug conjugates, protein-drug conjugates, other therapeutic applications}, research & development, □diagnostics), end user (pharmaceutical & biotechnology companies, CROs & CMOs, academic & research institutes, hospitals and clinical/diagnostic laboratories), service type (□custom synthesis & conjugation services, analytical & characterization services, scale-up & manufacturing services, □other services), technique (chemical conjugation, click chemistry, enzyme-mediated conjugation, photoreactive crosslinking, other techniques), conjugation type (antibody conjugation, peptide conjugation, protein conjugation, oligonucleotide conjugation, □other conjugation services), application (therapeutics, research & development, □diagnostics), end user (pharmaceutical & biotechnology companies, academic & research institutes, hospitals and clinical/diagnostic laboratories), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the bioconjugation market. A thorough analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. Also, it includes new product launches, collaborations and acquisitions, and recent developments associated with the bioconjugation market.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

## Reasons to buy this report

The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the overall bioconjugation market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

- Analysis of key drivers (growing demand for targeted therapies, increasing investments in biopharmaceutical R&D, rising demand for outsourcing services, expanding pipeline of bioconjugated drugs, advancements in bioconjugation technologies), restraints (high cost of bioconjugate development & manufacturing, stringent regulatory requirements), opportunities (high growth potential of emerging economies, expanding applications of bioconjugation), and Challenges (technical complexities) influencing the growth of the market.
- Product/Service Development/Innovation: Detailed insights on newly launched products/services of the bioconjugation market
- Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the bioconjugation market
- Competitive Assessment: In-depth assessment of market shares, growth strategies and product/service offerings of leading players like Danaher Corporation (US), Lonza (Switzerland), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), AbbVie Inc. (US), WuXi Biologics (Cayman) Inc. (China), Sartorius AG (Germany), Bio-Rad Laboratories, Inc. (US), among others in the market.

## Table of Contents:

1□INTRODUCTION□	58
1.1□STUDY OBJECTIVES□	58
1.2□MARKET DEFINITION□	58
1.3□MARKET SCOPE□	58
1.3.1□MARKETS COVERED□	59
1.3.2□INCLUSIONS & EXCLUSIONS□	60
1.3.3□YEARS CONSIDERED□	61
1.3.4□CURRENCY CONSIDERED□	61
1.4□MARKET STAKEHOLDERS□	61
2□RESEARCH METHODOLOGY□	62
2.1□RESEARCH DATA□	62
2.1.1□SECONDARY DATA□	63
2.1.2□PRIMARY DATA□	63
2.2□MARKET ESTIMATION METHODOLOGY□	65
2.2.1□MARKET ESTIMATION□	65
2.2.2□INSIGHTS FROM PRIMARY EXPERTS□	68
2.2.3□TOP-DOWN APPROACH□	68
2.3□MARKET GROWTH RATE PROJECTION□	70
2.4□DATA TRIANGULATION□	72
2.5□RESEARCH ASSUMPTIONS□	73
2.6□RESEARCH LIMITATIONS□	74
2.7□RISK ANALYSIS□	74
3□EXECUTIVE SUMMARY□	75
4□PREMIUM INSIGHTS□	83
4.1□BIOCONJUGATION MARKET OVERVIEW□	83
4.2□NORTH AMERICA: BIOCONJUGATION PRODUCTS MARKET,	

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

BY APPLICATION AND COUNTRY (2023)	84
4.3 BIOCONJUGATION PRODUCTS MARKET, BY TYPE (2023)	84
4.4 BIOCONJUGATION PRODUCTS MARKET, BY END USER (2023)	85
4.5 BIOCONJUGATION SERVICES MARKET, BY TYPE (2023)	85
4.6 BIOCONJUGATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES	86
?	
5 MARKET OVERVIEW	87
5.1 INTRODUCTION	87
5.2 MARKET DYNAMICS	88
5.2.1 DRIVERS	89
5.2.1.1 Growing demand for targeted therapies	89
5.2.1.2 Increasing investments in biopharmaceutical R&D	90
5.2.1.3 Rising demand for outsourcing services	91
5.2.1.4 Expanding pipeline of bioconjugate drugs	92
5.2.1.5 Advancements in bioconjugation technologies	93
5.2.2 RESTRAINTS	94
5.2.2.1 High cost of bioconjugate development & manufacturing	94
5.2.2.2 Stringent regulatory requirements	95
5.2.3 OPPORTUNITIES	95
5.2.3.1 High growth potential of emerging economies	95
5.2.3.2 Expanding applications of bioconjugation	96
5.2.4 CHALLENGES	96
5.2.4.1 Technical complexities	96
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	97
5.4 PRICING ANALYSIS	98
5.4.1 INDICATIVE PRODUCT PRICING ANALYSIS, BY KEY PLAYER	98
5.4.2 INDICATIVE PRODUCT PRICING ANALYSIS, BY REGION	99
5.5 SUPPLY CHAIN ANALYSIS	100
5.6 VALUE CHAIN ANALYSIS	102
5.7 ECOSYSTEM ANALYSIS	104
5.7.1 BIOCONJUGATION MARKET: RAW MATERIAL SUPPLIERS	104
5.7.2 BIOCONJUGATION MARKET: PRODUCT MANUFACTURERS	105
5.7.3 BIOCONJUGATION MARKET: SERVICE PROVIDERS	105
5.7.4 BIOCONJUGATION MARKET: END USERS	106
5.7.5 BIOCONJUGATION MARKET: REGULATORY BODIES	106
5.8 TECHNOLOGY ANALYSIS	107
5.8.1 KEY TECHNOLOGIES	107
5.8.1.1 Chemical conjugation	107
5.8.1.2 Enzymatic conjugation	108
5.8.1.3 Photochemical conjugation	109
5.8.1.4 Click chemistry	109
5.8.2 COMPLEMENTARY TECHNOLOGIES	109
5.8.3 ADJACENT TECHNOLOGIES	111
5.9 PATENT ANALYSIS	112
5.10 KEY CONFERENCES & EVENTS, 2025-2026	114
?	
5.11 REGULATORY ANALYSIS	115

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.11.1	REGULATORY LANDSCAPE	115
5.11.1.1	North America	116
5.11.1.1.1	US	116
5.11.1.1.2	Canada	116
5.11.1.2	Europe	116
5.11.1.2.1	Germany	117
5.11.1.2.2	UK	117
5.11.1.3	Asia Pacific	117
5.11.1.3.1	Japan	117
5.11.1.3.2	China	117
5.11.1.4	Latin America	117
5.11.1.4.1	Brazil	117
5.11.2	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	118
5.12	INVESTMENT & FUNDING SCENARIO	121
5.13	PORTER'S FIVE FORCES ANALYSIS	122
5.13.1	THREAT OF NEW ENTRANTS	123
5.13.2	THREAT OF SUBSTITUTES	123
5.13.3	BARGAINING POWER OF BUYERS	124
5.13.4	BARGAINING POWER OF SUPPLIERS	124
5.13.5	INTENSITY OF COMPETITIVE RIVALRY	124
5.14	KEY STAKEHOLDERS AND BUYING CRITERIA	125
5.14.1	KEY STAKEHOLDERS IN BUYING PROCESS	125
5.14.2	BUYING CRITERIA FOR END USERS	126
5.15	TRADE ANALYSIS	128
5.16	IMPACT OF AI/GENERATIVE AI ON BIOCONJUGATION MARKET	131
6	BIOCONJUGATION PRODUCTS MARKET, BY TYPE	133
6.1	INTRODUCTION	134
6.2	CONSUMABLES	134
6.2.1	REAGENTS & KITS	138
6.2.1.1	Linker and crosslinking reagents & kits	141
6.2.1.1.1	Precision in conjugation reactions to boost demand	141
6.2.1.2	Labeling reagents & kits	144
6.2.1.2.1	Growing demand for enhanced diagnostic sensitivity to fuel uptake	144
6.2.1.3	Modification reagents & kits	147
6.2.1.3.1	Uptake of protein engineering for optimal behavior to support market growth	147
6.2.1.4	Other reagents & kits	150
?		
6.2.2	LABELS	153
6.2.2.1	Fluorescent tags	156
6.2.2.1.1	Rising demand in imaging & diagnostics to drive market	156
6.2.2.2	Enzymes	159
6.2.2.2.1	Increasing utilization of western blotting & ELISA kits to fuel market	159
6.2.2.3	Haptens	162
6.2.2.3.1	Wide applications in immunoassays and vaccine development to support market growth	162
6.2.2.4	Polymers	165
6.2.2.4.1	Advancements in polymer-based drug delivery systems to drive market	165
6.2.2.5	Bead coupling	168

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

6.2.2.5.1	Utilization in magnetic bead-based immunoassays and cell separation to support market growth	168
6.2.2.6	Other labels	171
6.2.3	OTHER CONSUMABLES	174
6.3	INSTRUMENTS	177
6.3.1	CHROMATOGRAPHY SYSTEMS	180
6.3.1.1	Ability to offer precision and purification to drive market	180
6.3.2	MASS SPECTROMETERS	183
6.3.2.1	High uptake in bioconjugate characterization to drive market	183
6.3.3	SPECTROSCOPY INSTRUMENTS	186
6.3.3.1	Monitoring of bioconjugation reactions in real-time to fuel uptake	186
6.3.4	FLOW CYTOMETERS	189
6.3.4.1	Determination of therapeutic potential in ADCs to propel market	189
6.3.5	ELECTROPHORESIS EQUIPMENT	192
6.3.5.1	Increasing requirement for reliable analysis to support market growth	192
6.3.6	FILTRATION SYSTEMS	195
6.3.6.1	High purity requirements to support market growth	195
6.3.7	MIXERS & SHAKERS	198
6.3.7.1	Ability to ensure uniform conjugation reactions to boost demand	198
6.3.8	INCUBATORS	200
6.3.8.1	Integration of smart technologies for controlled environments to drive market	200
6.3.9	OTHER INSTRUMENTS	203
7	BIOCONJUGATION PRODUCTS MARKET, BY TECHNIQUE	206
7.1	INTRODUCTION	207
7.2	CHEMICAL CONJUGATION	207
7.2.1	HIGH DEMAND FOR ONCOLOGY ADCS AND VERSATILE TECHNIQUE TO PROPEL MARKET	207
7.3	CLICK CHEMISTRY	211
7.3.1	GROWING NEED FOR REGULATORY COMPLIANCE AND QUALITY ASSURANCE TO PROPEL MARKET	211
7.4	ENZYME-MEDIATED CONJUGATION	214
7.4.1	INCREASING NUMBER OF CLINICAL TRIALS TO BOOST DEMAND	214
7.5	PHOTOREACTIVE CROSSLINKING	217
7.5.1	DEVELOPMENT OF LIGHT-ACTIVATED THERAPEUTICS AND IMAGING AGENTS TO SUPPORT MARKET GROWTH	217
7.6	OTHER TECHNIQUES	220
8	BIOCONJUGATION PRODUCTS MARKET, BY BIOMOLECULE TYPE	224
8.1	INTRODUCTION	225
8.2	ANTIBODIES	225
8.2.1	EXPANDING THERAPEUTIC APPLICATIONS TO SUPPORT MARKET GROWTH	225
8.3	PEPTIDES	228
8.3.1	HIGH FLEXIBILITY AND DRUG DELIVERY EFFICIENCY TO FUEL UPTAKE	228
8.4	PROTEINS	231
8.4.1	INCREASING DEVELOPMENT OF ELISA AND PDCS IN THERAPEUTIC APPLICATIONS TO DRIVE MARKET	231
8.5	OLIGONUCLEOTIDES	234
8.5.1	GROWING UPTAKE IN GENE THERAPY TO SUPPORT MARKET	234
8.6	OTHER BIOMOLECULES	237
9	BIOCONJUGATION PRODUCTS MARKET, BY APPLICATION	240
9.1	INTRODUCTION	241
9.2	THERAPEUTICS	241

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

9.2.1	ANTIBODY-DRUG CONJUGATES	246
9.2.1.1	Increasing demand for targeted cancer therapies to propel market	246
9.2.2	PEPTIDE-DRUG CONJUGATES	249
9.2.2.1	Advancements in peptide synthesis to boost demand	249
9.2.3	PROTEIN-DRUG CONJUGATES	253
9.2.3.1	Improvements in bioavailability and pharmacokinetics of therapeutic agents to drive market	253
9.2.4	OTHER THERAPEUTIC APPLICATIONS	256
9.3	RESEARCH & DEVELOPMENT	259
9.3.1	GROWING INTEREST IN INNOVATIVE THERAPEUTIC MODALITIES TO DRIVE MARKET	259
9.4	DIAGNOSTICS	262
9.4.1	UTILIZATION IN DIAGNOSTIC ASSAY DEVELOPMENT TO SUPPORT MARKET GROWTH	262
10	BIOCONJUGATION PRODUCTS MARKET, BY END USER	266
10.1	INTRODUCTION	267
10.2	PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES	267
10.2.1	INCREASING ADOPTION OF BIOCONJUGATION IN TARGETED THERAPIES TO DRIVE MARKET	267
10.3	CONTRACT RESEARCH ORGANIZATIONS (CRO) & CONTRACT MANUFACTURING ORGANIZATIONS (CMO)	271
10.3.1	INCREASING OUTSOURCING OF BIOCONJUGATION SERVICES TO PROPEL MARKET	271
10.4	ACADEMIC & RESEARCH INSTITUTES	274
10.4.1	INCREASING FOCUS ON NOVEL BIOCONJUGATION TECHNIQUES FOR BASIC & APPLIED RESEARCH TO FUEL UPTAKE	274
10.5	HOSPITALS AND CLINICAL/DIAGNOSTIC LABORATORIES	277
10.5.1	EXPANDING APPLICATIONS OF BIOCONJUGATES IN DIAGNOSTICS & THERAPEUTICS TO SUPPORT MARKET GROWTH	277
11	BIOCONJUGATION SERVICES MARKET, BY TYPE	281
11.1	INTRODUCTION	282
11.2	CUSTOM SYNTHESIS & CONJUGATION SERVICES	282
11.2.1	GROWING NEED FOR TARGETED & CUSTOMIZED THERAPIES TO DRIVE MARKET	282
11.3	ANALYTICAL & CHARACTERIZATION SERVICES	286
11.3.1	GROWING FOCUS ON REGULATORY COMPLIANCE TO FUEL UPTAKE	286
11.4	SCALE-UP & MANUFACTURING SERVICES	289
11.4.1	INCREASING COMMERCIALIZATION OF BIOCONJUGATED DRUGS TO SUPPORT MARKET GROWTH	289
11.5	OTHER SERVICES	292
12	BIOCONJUGATION SERVICES MARKET, BY CONJUGATION TYPE	295
12.1	INTRODUCTION	296
12.2	ANTIBODY CONJUGATION	296
12.2.1	ABILITY TO LINK ANTIBODIES TO PAYLOADS FOR SPECIALIZED THERAPEUTICS TO PROPEL MARKET	296
12.3	PEPTIDE CONJUGATION	300
12.3.1	IMPROVED STABILITY & BIOAVAILABILITY TO DRIVE MARKET	300
12.4	PROTEIN CONJUGATION	303
12.4.1	LINKING PROTEINS WITH DRUGS FOR TARGETED DELIVERY TO FUEL UPTAKE	303
12.5	OLIGONUCLEOTIDE CONJUGATION	307
12.5.1	ADVANCEMENTS IN NUCLEIC ACID-BASED THERAPEUTICS TO SUPPORT MARKET GROWTH	307
12.6	OTHER CONJUGATION SERVICES	310
13	BIOCONJUGATION SERVICES MARKET, BY TECHNIQUE	314
13.1	INTRODUCTION	315
13.2	CHEMICAL CONJUGATION	315
13.2.1	ESSENTIAL TECHNIQUE FOR DEVELOPMENT OF CUSTOM BIOCONJUGATES TO FUEL UPTAKE	315
13.3	CLICK CHEMISTRY	319

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

13.3.1	PROVISION OF HIGH YIELD FOR DEVELOPMENT OF COMPLEX BIOCONJUGATES TO PROPEL MARKET	319
13.4	ENZYME-MEDIATED CONJUGATION	322
13.4.1	NEED FOR PRECISE & STABLE CONJUGATES IN COMPLEX THERAPEUTIC MODALITIES TO DRIVE MARKET	322
13.5	PHOTOREACTIVE CROSSLINKING	325
13.5.1	ABILITY TO PROVIDE CONTROLLED & SITE-SPECIFIC FORMATION OF CROSSLINKS TO SUPPORT MARKET GROWTH	325
13.6	OTHER TECHNIQUES	328
14	BIOCONJUGATION SERVICES MARKET, BY APPLICATION	331
14.1	INTRODUCTION	332
14.2	THERAPEUTICS	332
14.2.1	STRATEGIC PARTNERSHIPS BETWEEN BIOPHARMA COMPANIES AND BIOCONJUGATION SERVICE PROVIDERS TO PROPEL MARKET	332
14.3	RESEARCH & DEVELOPMENT	336
14.3.1	GROWING FOCUS ON BIOMOLECULAR RESEARCH INNOVATION TO DRIVE MARKET	336
14.4	DIAGNOSTICS	339
14.4.1	DEVELOPMENT OF ADVANCED IMAGING TECHNOLOGIES AND BIOSENSORS TO SUPPORT MARKET GROWTH	339
15	BIOCONJUGATION SERVICES MARKET, BY END USER	343
15.1	INTRODUCTION	344
15.2	PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES	344
15.2.1	ADVANCEMENTS IN DRUG DISCOVERY & DEVELOPMENT TO PROPEL MARKET	344
15.3	ACADEMIC & RESEARCH INSTITUTES	348
15.3.1	INNOVATION IN CONJUGATION TECHNIQUES AND BIOMEDICAL RESEARCH TO DRIVE MARKET	348
15.4	HOSPITALS AND CLINICAL/DIAGNOSTIC LABORATORIES	351
15.4.1	INCREASING DEMAND FOR PRECISION DIAGNOSTICS TO FUEL UPTAKE	351
16	BIOCONJUGATION MARKET, BY REGION	354
16.1	INTRODUCTION	355
16.2	NORTH AMERICA	356
16.2.1	MACROECONOMIC OUTLOOK OF NORTH AMERICA	365
16.2.2	US	365
16.2.2.1	High healthcare expenditure to propel market	365
16.2.3	CANADA	372
16.2.3.1	Increasing government funding for drug development to support market growth	372
16.3	EUROPE	379
16.3.1	MACROECONOMIC OUTLOOK OF EUROPE	386
16.3.2	GERMANY	387
16.3.2.1	Facility expansion by key players to aid market growth	387
16.3.3	UK	394
16.3.3.1	Increased cancer prevalence and government funding for pharmaceutical & biotechnology research to fuel uptake	394
16.3.4	FRANCE	400
16.3.4.1	Favorable government initiatives and growing demand for personalized therapeutics to boost demand	400
16.3.5	ITALY	406
16.3.5.1	Increasing industrial collaborations for ADC production to support market growth	406
16.3.6	SPAIN	412
16.3.6.1	Growing preference for personalized medicine to drive market	412
16.3.7	REST OF EUROPE	418
16.4	ASIA PACIFIC	425
16.4.1	MACROECONOMIC OUTLOOK OF ASIA PACIFIC	433
16.4.2	CHINA	434

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



16.4.2.1	Expansion of biopharmaceutical manufacturing facilities to boost demand	434
16.4.3	JAPAN	441
16.4.3.1	Increasing collaborations among biotechnology companies to support market growth	441
16.4.4	INDIA	448
16.4.4.1	High investments in pharma R&D and favorable government policies to boost demand	448
16.4.5	SOUTH KOREA	454
16.4.5.1	Increased focus on quality manufacturing practices to propel market	454
16.4.6	AUSTRALIA	461
16.4.6.1	Growing demand for innovative research solutions to drive market	461
16.4.7	REST OF ASIA PACIFIC	467
16.5	LATIN AMERICA	474
16.5.1	MACROECONOMIC OUTLOOK OF LATIN AMERICA	481
16.5.2	BRAZIL	482
16.5.2.1	Increasing pharmaceutical R&D to fuel market	482
16.5.3	MEXICO	489
16.5.3.1	High FDIs and reduced pharmaceutical manufacturing costs to drive market	489
16.5.4	REST OF LATIN AMERICA	495
?		
16.6	MIDDLE EAST	502
16.6.1	MACROECONOMIC OUTLOOK OF MIDDLE EAST	509
16.6.2	GCC COUNTRIES	510
16.6.2.1	Kingdom of Saudi Arabia	517
16.6.2.1.1	Rising healthcare expenditure to boost market	517
16.6.2.2	United Arab Emirates	524
16.6.2.2.1	Increasing collaborations among biopharma companies to aid market growth	524
16.6.2.3	Other GCC Countries	530
16.6.3	REST OF MIDDLE EAST	537
16.7	AFRICA	544
16.7.1	INCREASING TARGET PATIENT POOL TO SUPPORT MARKET GROWTH	544
16.7.2	MACROECONOMIC OUTLOOK OF AFRICA	550
17	COMPETITIVE LANDSCAPE	552
17.1	OVERVIEW	552
17.2	KEY PLAYER STRATEGY/RIGHT TO WIN	552
17.2.1	OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN BIOCONJUGATION MARKET	553
17.3	REVENUE ANALYSIS, 2019-2023	554
17.4	MARKET SHARE ANALYSIS, 2023	555
17.5	COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023	557
17.5.1	STARS	557
17.5.2	EMERGING LEADERS	557
17.5.3	PERVASIVE PLAYERS	557
17.5.4	PARTICIPANTS	558
17.5.5	COMPANY FOOTPRINT: KEY PLAYERS, 2023	559
17.5.5.1	Company footprint	559
17.5.5.2	Product/Service footprint	560
17.5.5.3	Application footprint	561
17.5.5.4	End-user footprint	562
17.5.5.5	Region footprint	564

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

17.6	COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023	565
17.6.1	PROGRESSIVE COMPANIES	565
17.6.2	RESPONSIVE COMPANIES	565
17.6.3	DYNAMIC COMPANIES	565
17.6.4	STARTING BLOCKS	566
17.6.5	COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023	567
17.7	COMPANY VALUATION & FINANCIAL METRICS	570
17.7.1	FINANCIAL METRICS	570
17.7.2	COMPANY VALUATION	570
	?	
17.8	BRAND/PRODUCT/SERVICE COMPARISON	571
17.9	COMPETITIVE SCENARIO	572
17.9.1	PRODUCT/SERVICE LAUNCHES	572
17.9.2	DEALS	573
17.9.3	EXPANSIONS	574
18	COMPANY PROFILES	576
18.1	KEY PLAYERS	576
18.1.1	DANAHER CORPORATION	576
18.1.1.1	Business overview	576
18.1.1.2	Products/Services offered	577
18.1.1.3	Recent developments	586
18.1.1.3.1	Product/Service launches	586
18.1.1.3.2	Deals	587
18.1.1.3.3	Expansions	587
18.1.1.4	MnM view	588
18.1.1.4.1	Key strengths	588
18.1.1.4.2	Strategic choices	588
18.1.1.4.3	Weaknesses & competitive threats	589
18.1.2	LONZA	590
18.1.2.1	Business overview	590
18.1.2.2	Products/Services offered	591
18.1.2.3	Recent developments	592
18.1.2.3.1	Deals	592
18.1.2.3.2	Expansions	593
18.1.2.4	MnM view	593
18.1.2.4.1	Key strengths	593
18.1.2.4.2	Strategic choices	594
18.1.2.4.3	Weaknesses & competitive threats	594
18.1.3	THERMO FISHER SCIENTIFIC INC.	595
18.1.3.1	Business overview	595
18.1.3.2	Products/Services offered	596
18.1.3.3	Recent developments	602
18.1.3.3.1	Product/Service launches	602
18.1.3.3.2	Deals	603
18.1.3.3.3	Expansions	604
18.1.3.4	MnM view	605
18.1.3.4.1	Key strengths	605

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 18.1.3.4.2 Strategic choices 605
- 18.1.3.4.3 Weaknesses & competitive threats 605
- ?
- 18.1.4 MERCK KGAA 606
- 18.1.4.1 Business overview 606
- 18.1.4.2 Products/Services offered 607
- 18.1.4.3 Recent developments 611
- 18.1.4.3.1 Product/Service launches 611
- 18.1.4.3.2 Deals 612
- 18.1.4.3.3 Expansions 612
- 18.1.4.4 MnM view 614
- 18.1.4.4.1 Key strengths 614
- 18.1.4.4.2 Strategic choices 614
- 18.1.4.4.3 Weaknesses & competitive threats 614
- 18.1.5 ABBVIE INC. 615
- 18.1.5.1 Business overview 615
- 18.1.5.2 Products/Services offered 616
- 18.1.5.3 Recent developments 616
- 18.1.5.3.1 Deals 616
- 18.1.5.3.2 Expansions 617
- 18.1.5.4 MnM view 617
- 18.1.5.4.1 Key strengths 617
- 18.1.5.4.2 Strategic choices 617
- 18.1.5.4.3 Weaknesses & competitive threats 617
- 18.1.6 WUXI BIOLOGICS (CAYMAN) INC. 618
- 18.1.6.1 Business overview 618
- 18.1.6.2 Products/Services offered 619
- 18.1.6.3 Recent developments 620
- 18.1.6.3.1 Deals 620
- 18.1.6.3.2 Expansions 622
- 18.1.7 SARTORIUS AG 623
- 18.1.7.1 Business overview 623
- 18.1.7.2 Products/Services offered 624
- 18.1.7.3 Recent developments 626
- 18.1.7.3.1 Deals 626
- 18.1.7.3.2 Expansions 627
- 18.1.8 BIO-RAD LABORATORIES, INC. 628
- 18.1.8.1 Business overview 628
- 18.1.8.2 Products/Services offered 629
- ?
- 18.1.9 CATALENT, INC. 633
- 18.1.9.1 Business overview 633
- 18.1.9.2 Products/Services offered 634
- 18.1.9.3 Recent developments 635
- 18.1.9.3.1 Product/Service launches 635
- 18.1.9.3.2 Deals 635
- 18.1.9.3.3 Expansions 636

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

18.1.10	BECKTON, DICKINSON AND COMPANY	637
18.1.10.1	Business overview	637
18.1.10.2	Products/Services offered	638
18.1.10.3	Recent developments	640
18.1.10.3.1	Product/Service launches	640
18.1.10.3.2	Deals	640
18.1.11	AGILENT TECHNOLOGIES, INC.	641
18.1.11.1	Business overview	641
18.1.11.2	Products/Services offered	642
18.1.11.3	Recent developments	644
18.1.11.3.1	Product/Service launches	644
18.1.11.3.2	Deals	644
18.1.11.3.3	Expansions	646
18.1.12	PROMEGA CORPORATION	647
18.1.12.1	Business overview	647
18.1.12.2	Products/Services offered	647
18.1.13	F. HOFFMANN-LA ROCHE LTD.	648
18.1.13.1	Business overview	648
18.1.13.2	Products/Services offered	649
18.1.14	CHARLES RIVER LABORATORIES	651
18.1.14.1	Business overview	651
18.1.14.2	Products/Services offered	652
18.1.14.3	Recent developments	653
18.1.14.3.1	Deals	653
18.1.15	GENSCRIPT BIOTECH CORPORATION	654
18.1.15.1	Business overview	654
18.1.15.2	Products/Services offered	655
18.1.15.3	Recent developments	656
18.1.15.3.1	Deals	656
18.1.16	PIRAMAL PHARMA LIMITED	657
18.1.16.1	Business overview	657
18.1.16.2	Products/services offered	658
18.1.16.3	Recent developments	659
18.1.16.3.1	Product/Service launches	659
18.1.16.3.2	Expansions	659
18.2	OTHER PLAYERS	660
18.2.1	ABZENA LTD.	660
18.2.2	NEW ENGLAND BIOLABS	661
18.2.3	BIOSYNTH	662
18.2.4	CELL SIGNALING TECHNOLOGY, INC.	663
18.2.5	CREATIVE BIOLABS	664
18.2.6	FORMOSA LABORATORIES INC.	665
18.2.7	NJ BIO, INC.	666
18.2.8	ROCKLAND IMMUNOCHEMICALS, INC.	667
18.2.9	SHANGHAI CHEMPARTNER	668
18.2.10	STERLING PHARMA SOLUTIONS LIMITED	668
18.2.11	SYNGENE INTERNATIONAL LIMITED	669

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

18.2.12 TOKYO CHEMICAL INDUSTRY CO., LTD. 670

18.2.13 VECTOR LABORATORIES, INC. 671

19 APPENDIX 672

19.1 DISCUSSION GUIDE 672

19.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL 678

19.3 CUSTOMIZATION OPTIONS 680

19.4 RELATED REPORTS 681

19.5 AUTHOR DETAILS 682

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Bioconjugation Market by Product (Consumables, Instruments (Chromatography, Spectrometry)), Service (Conjugation, Analytical), Technique (Chemical, Click Chemistry), Biomolecule (Antibodies), Application (Therapeutics (ADC), R&D) - Global Forecast to 2029**

Market Report | 2025-02-01 | 683 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	2025-05-13
		Signature	<div></div>